The presentation will be webcast live and can be accessed through the Investor Relations page at www.sophiris.com. A replay of the presentation will be available on the Company's website for 90 days.
Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin has successfully completed a Phase 2a clinical trial for the treatment of localized low to intermediate risk prostate cancer. Topsalysin has also successfully completed a Phase 3 clinical study for the treatment of the symptoms of benign prostatic hyperplasia (BPH), and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. For more information, please visit www.sophiris.com.
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris' current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Chief Financial Officer
Corporate Communications and Investor Relations:
Corporate Communications and IR
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sophiris-bio-to-present-at-28th-annual-piper-jaffray-healthcare-conference-300366994.html
News Provided by Acquire Media